Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rifabutin

FDA-approved product (capsule, oral), marketed as Mycobutin, Rifabutin.

Registered studies
50+
Lab records
15
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Rifabutin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Mycobacterium avium complex disease
  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics
FDA pharmacologic class
Rifamycin Antimycobacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AB04; FDA class Rifamycin Antimycobacterial

Repurposing investigation

Rifabutin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA84.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli64.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 15 of 15 lab records
Open Rifabutin in ChEMBL Registered studies below
Show the 15 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rifabutin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)

    NCT04630145 · start 2021-01-08

    Registered record
    Registry ID
    NCT04630145
    Conditions
    Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)
    Interventions
    Bedaquiline; Clarithromycin; Ethambutol; Rifampicin; Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2021-01-08
    Completion
    2025-11-14
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTreatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)
    InterventionBedaquiline; Clarithromycin; Ethambutol; Rifampicin +1 more
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease

    NCT04553406 · start 2020-12-03

    Registered record
    Registry ID
    NCT04553406
    Conditions
    Mycobacterium Avium Complex; Non-tuberculous Mycobacterium Pulmonary Disease
    Interventions
    SPR720; Placebo; Open-label Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2020-12-03
    Completion
    2021-01-28
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Avium Complex; Non-tuberculous Mycobacterium Pulmonary Disease
    InterventionSPR720; Placebo; Open-label Standard of Care
    PhasePhase 2
    Registry statusTerminated

  • RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease

    NCT04616924 · start 2020-12-01

    Registered record
    Registry ID
    NCT04616924
    Conditions
    Pulmonary Mycobacterium Avium Complex Infection; Bronchiectasis; Lung Diseases
    Interventions
    RHB-204; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2020-12-01
    Completion
    2023-08-28
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Mycobacterium Avium Complex Infection; Bronchiectasis; Lung Diseases
    InterventionRHB-204; Placebo
    PhasePhase 3
    Registry statusTerminated

  • Susceptibility Testing Guided Versus Empirical Therapy for Refractory H. Pylori Infection

    NCT04332848 · start 2020-07-28

    Registered record
    Registry ID
    NCT04332848
    Conditions
    Helicobacter Pylori Infection
    Interventions
    ET; SGT
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2020-07-28
    Completion
    2026-12
    Enrolment
    360

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionET; SGT
    PhasePhase 4
    Registry statusRecruiting

  • Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

    NCT04310930 · start 2020-03-02

    Registered record
    Registry ID
    NCT04310930
    Conditions
    Pulmonary Disease Due to Mycobacteria (Diagnosis)
    Interventions
    Amikacin; Tigecycline; Imipenem; Cefoxitin; Azithromycin; Clarithromycin; Clofazimine; Ethambutol; Amikacin; Linezolid; co-trimoxazole; Doxycycline; Moxifloxacin; Bedaquiline; Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2020-03-02
    Completion
    2030-06-30
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Disease Due to Mycobacteria (Diagnosis)
    InterventionAmikacin; Tigecycline; Imipenem; Cefoxitin +11 more
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Genotypic Resistance-guided Versus Empirical Therapy for H. Pylori Eradication.

    NCT04090021 · start 2019-09-01

    Registered record
    Registry ID
    NCT04090021
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Esomeprazole 40mg; Clarithromycin 500mg; Metronidazole 500 mg; Amoxicillin 1000 MG; Levofloxacin 500mg; Rifabutin 150 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-09-01
    Completion
    2020-02-28
    Enrolment
    304

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionEsomeprazole 40mg; Clarithromycin 500mg; Metronidazole 500 mg; Amoxicillin 1000 MG +2 more
    PhasePhase 4
    Registry statusUnknown

  • Anti-chlamydophila Antibiotic Combination Therapy in the Treatment of Patients With Coronary Heart Disease

    NCT03618108 · start 2018-04-04

    Registered record
    Registry ID
    NCT03618108
    Conditions
    Coronary Heart Disease; Chlamydophila Pneumoniae Infections
    Interventions
    Doxycycline Capsule; Azithromycin Capsule; Rifabutin Oral Capsule; Placebo oral capsule; Placebo Oral Tablet; Placebo oral capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2018-04-04
    Completion
    2020-11-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Heart Disease; Chlamydophila Pneumoniae Infections
    InterventionDoxycycline Capsule; Azithromycin Capsule; Rifabutin Oral Capsule; Placebo oral capsule +2 more
    PhasePhase 2
    Registry statusTerminated

  • Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects

    NCT03149848 · start 2017-06-06

    Registered record
    Registry ID
    NCT03149848
    Conditions
    Infection, Human Immunodeficiency Virus; HIV Infections
    Interventions
    Cabotegravir; Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-06-06
    Completion
    2017-09-07
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus; HIV Infections
    InterventionCabotegravir; Rifabutin
    PhasePhase 1
    Registry statusCompleted

  • TB Host Directed Therapy

    NCT02968927 · start 2016-11

    Registered record
    Registry ID
    NCT02968927
    Conditions
    Tuberculosis
    Interventions
    Everolimus 0.5 MG; Auranofin 6 MG; Vitamin D3; CC-11050; 2HRbZE/4HRb
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2016-11
    Completion
    2020-12
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionEverolimus 0.5 MG; Auranofin 6 MG; Vitamin D3; CC-11050 +1 more
    PhasePhase 2
    Registry statusUnknown

  • Assessing PA-824 for Tuberculosis (the APT Trial)

    NCT02256696 · start 2015-04-29

    Registered record
    Registry ID
    NCT02256696
    Conditions
    Pulmonary Tuberculosis
    Interventions
    PA-824; Rifampin; Rifabutin; Pyrazinamide; Ethambutol; Isoniazid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-04-29
    Completion
    2022-05-01
    Enrolment
    157

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionPA-824; Rifampin; Rifabutin; Pyrazinamide +2 more
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease

    NCT01951326 · start 2013-09

    Registered record
    Registry ID
    NCT01951326
    Conditions
    Crohn's Disease
    Interventions
    RHB-104; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-09
    Completion
    2019-08
    Enrolment
    331

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCrohn's Disease
    InterventionRHB-104; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)

    NCT01717664 · start 2013-06

    Registered record
    Registry ID
    NCT01717664
    Conditions
    Relapsing Remitting Multiple Sclerosis
    Interventions
    RHB-104
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-06
    Completion
    2016-07
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsing Remitting Multiple Sclerosis
    InterventionRHB-104
    PhasePhase 2
    Registry statusCompleted

  • A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc

    NCT01894776 · start 2013-06

    Registered record
    Registry ID
    NCT01894776
    Conditions
    HIV Infection; HIV-1 Infection; Mycobacterium Avium Complex (MAC)
    Interventions
    Rifabutin; Maraviroc
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-06
    Completion
    2015-02
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection; HIV-1 Infection; Mycobacterium Avium Complex (MAC)
    InterventionRifabutin; Maraviroc
    PhasePhase 1
    Registry statusCompleted

  • Research on New Regimens for Retreatment Pulmonary Tuberculosis

    NCT02331823 · start 2013-06

    Registered record
    Registry ID
    NCT02331823
    Conditions
    Reinfection Pulmonary Tuberculosis
    Interventions
    Isoniazid Aminosalicylate Tablets; Streptomycin injectable
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2013-06
    Completion
    2016-12
    Enrolment
    864

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionReinfection Pulmonary Tuberculosis
    InterventionIsoniazid Aminosalicylate Tablets; Streptomycin injectable
    PhasePhase 4
    Registry statusUnknown

  • EARNEST Rifabutin Pharmacokinetics (PK) Substudy

    NCT01663168 · start 2011-12

    Registered record
    Registry ID
    NCT01663168
    Conditions
    HIV; Tuberculosis
    Interventions
    Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2011-12
    Completion
    2014-01
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Tuberculosis
    InterventionRifabutin
    PhasePhase 2
    Registry statusUnknown